Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535 Favorable overall safety, tolerability, and pharmacokinetic profile of LHF-535 f ...
Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses
Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses Seattle, WA -- (July 15, 2019) Kineta, Inc., a clinical stage biotechnology company focused on the development of nove ...
Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference
Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference Seattle, WA -- (May 28, 2019) Kineta, Inc., a clinical stage biotechnology company focused on the develop ...
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up t ...